IQCF1 Inhibitors
IQCF1 Inhibitors are a group of chemical compounds that indirectly diminish the functional activity of IQCF1 through various signaling pathways. GW 5074, as a Raf-1 kinase inhibitor, disrupts the upstream activation of the MEK/ERK pathway, leading to decreased phosphorylation of proteins that could include IQCF1, thereby reducing its activity. In a similar vein, U0126 and PD 98059, which selectively inhibit MEK1/2, and BIX 02189, which targets MEK5, prevent the activation of downstream ERK kinases, potentially resulting in diminished functional activity of IQCF1 if it is modulated by these pathways. SB 203580 and SP600125 specifically target p38 MAPK and JNK signaling pathways, respectively. By doing so, they attenuate the regulatory effects these pathways may exert on IQCF1. Moreover, SL-327, by blocking MEK1 and MEK2, further contributes to decreased ERK1/2 signaling and subsequent potential reduction in IQCF1 activity.
Compounds like LY 294002 and Wortmannin act as potent inhibitors of PI3K, diminishing the PI3K/Akt signaling pathway, which, if involved in regulating IQCF1, would result in reduced functional activity. Rapamycin, an mTOR inhibitor, disrupts mTORC1 signaling, potentially affecting protein translation processes that may involve IQCF1. PP 2, by inhibiting Src family kinases, and Gö 6983, as a PKC pathway inhibitor, both potentially lead to decreased functional activity of IQCF1 by lessening the phosphorylation and activation of proteins within these respective signaling cascades. Collectively, these inhibitors operate by targeting specific kinases and signaling pathways, leading to an indirect reduction in the functional activity of IQCF1 through a decrease in phosphorylation, activation, and signaling events related to its regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a potent inhibitor of Raf-1 kinase, which acts upstream of the MEK/ERK pathway. Inhibition of Raf-1 leads to reduced activity of downstream kinases, diminishing the phosphorylation and activity of proteins involved in this pathway, potentially including IQCF1 if it is regulated by this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K). By blocking PI3K activity, it diminishes the PI3K/Akt signaling pathway, which is implicated in various cellular processes including transcription regulation. This reduction in signaling could indirectly decrease the functional activity of IQCF1 if it is modulated by PI3K/Akt-mediated transcriptional events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes within the MAPK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK1/2, which may indirectly lead to reduced functional activity of IQCF1 through diminished phosphorylation and activation of proteins in this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK activity leads to decreased regulation of proteins influenced by the p38 signaling pathway, potentially diminishing the activity of IQCF1 if it is associated with this signaling axis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR). By inhibiting mTOR, rapamycin disrupts the mTORC1 signaling pathway, which could lead to a reduction in the functional activity of IQCF1 by decreasing protein translation and cell growth signaling that might involve IQCF1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which blocks the activation of the downstream kinase ERK. This leads to diminished signaling through the MAPK pathway and could reduce the functional activity of IQCF1 if its activity is modulated by ERK-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 diminishes the JNK signaling pathway, which could reduce the functional activity of IQCF1 if it is modulated by JNK-dependent cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By blocking PI3K activity, Wortmannin can reduce PI3K/Akt pathway signaling, potentially leading to decreased functional activity of IQCF1 if its activity is related to this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP 2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP 2 can potentially diminish the functional activity of IQCF1 if it is regulated by Src-dependent signaling pathways, through reduced phosphorylation and activation of downstream targets. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö 6983 is a pan-PKC inhibitor that diminishes protein kinase C (PKC) pathway signaling. The inhibition of PKC can lead to decreased regulation of proteins that are part of PKC signaling, potentially decreasing the functional activity of IQCF1 if it relies on PKC-mediated processes. | ||||||